0001193125-22-189000.txt : 20220707 0001193125-22-189000.hdr.sgml : 20220707 20220707071102 ACCESSION NUMBER: 0001193125-22-189000 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220707 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20220707 DATE AS OF CHANGE: 20220707 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 221070632 BUSINESS ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 d537481d8k.htm 8-K 8-K
false 0001783328 0001783328 2022-07-07 2022-07-07





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 7, 2022




(Exact name of registrant as specified in its charter)




Delaware   001-40603   82-5282075

(State or other jurisdiction

of incorporation)



File Number)


(I.R.S. Employer

Identification No.)

830 Winter Street

Waltham, Massachusetts 02451

(Address of principal executive offices, including zip code)

(857) 399-9500

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Voting Common Stock, $0.0001 par value per share   TCRX   The Nasdaq Global Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company   

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Chief Medical Officer

On July 7, 2022, TScan Therapeutics, Inc. (the “Company”), announced the appointment of Dr. Debora Barton, M.D., to serve as the Company’s Chief Medical Officer, effective July 5, 2022.

Dr. Barton, age 46, served as the Chief Medical Officer of Carisma Therapeutics, Inc. from November 2019 to June 2022, where she was responsible for clinical development, clinical operations, medical affairs, and safety. Previously Dr. Barton was the Senior Vice President, Head of Clinical, Head of Safety at Iovance Biotherapeutics, Inc. (“Iovance”), from May 2018 to November 2019, where she oversaw several Phase 2 studies in solid tumors and led clinical efforts related to regulatory interactions. Prior to Iovance, Dr. Barton held positions of increasing responsibility at biotech and pharmaceutical companies including various positions at Advanced Accelerator Applications from September 2016 to May 2018. Dr. Barton is a board-certified clinical oncologist (M.D.), and a board member for the American Cancer Society, the Tigerlily Foundation (medical advisory board), a national breast cancer foundation providing advocacy and support for young women before, during and after breast cancer, and Arovella Therapeutics Ltd (non-executive director). She holds an M.D. degree from Pontificia Universidade Catolica Sao Paulo and completed her fellowship in oncology at Federal University of Sao Paulo in Brazil.

There are (a) no understandings or arrangements between Dr. Barton and any other person pursuant to which she was appointed as Chief Medical Officer of the Company and (b) Dr. Barton has no material interest in any transaction or proposed transaction in which the Company is or is to be a party. Dr. Barton has no family relationship with any director or executive officer of the Company.

In connection with Dr. Barton’s appointment, the Company entered into an employment agreement with Dr. Barton. Dr. Barton’s employment agreement provides for a base salary of $450,000 per annum and an option to purchase 150,000 shares of the Company’s common stock under the Company’s 2021 Equity Incentive Plan. 25% of the shares subject to the option will vest after twelve (12) months of continuous service with vesting commencing on her first day of employment, and the balance will vest in thirty-six (36) equal monthly installments of continuous service. Dr. Barton is also eligible for a discretionary bonus target of up to 40% of her base salary during the period she serves as the Company’s Chief Medical Officer based on the achievement of certain performance goals, to be determined by the Board of Directors of the Company or its Compensation Committee. Dr. Barton is also eligible for certain severance and change of control payments consistent with those provided to other non-CEO executive officers of the Company. The forgoing summary is subject in all respects to the full text of Dr. Barton’s employment agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2022.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


   TScan Therapeutics, Inc.
Date: July 7, 2022    By:  

/s/ Brian Silver

     Brian Silver
     Chief Financial Officer
EX-101.SCH 2 tcrx-20220707.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 tcrx-20220707_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 tcrx-20220707_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Jul. 07, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001783328
Document Type 8-K
Document Period End Date Jul. 07, 2022
Entity Registrant Name TSCAN THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-40603
Entity Tax Identification Number 82-5282075
Entity Address, Address Line One 830 Winter Street
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code (857)
Local Phone Number 399-9500
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Voting Common Stock, $0.0001 par value per share
Trading Symbol TCRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 6 d537481d8k_htm.xml IDEA: XBRL DOCUMENT 0001783328 2022-07-07 2022-07-07 false 0001783328 8-K 2022-07-07 TSCAN THERAPEUTICS, INC. DE 001-40603 82-5282075 830 Winter Street Waltham MA 02451 (857) 399-9500 false false false false Voting Common Stock, $0.0001 par value per share TCRX NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d537481d8k.htm tcrx-20220707.xsd tcrx-20220707_lab.xml tcrx-20220707_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d537481d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d537481d8k.htm" ] }, "labelLink": { "local": [ "tcrx-20220707_lab.xml" ] }, "presentationLink": { "local": [ "tcrx-20220707_pre.xml" ] }, "schema": { "local": [ "tcrx-20220707.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tcrx", "nsuri": "http://www.tscan.com/20220707", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d537481d8k.htm", "contextRef": "duration_2022-07-07_to_2022-07-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d537481d8k.htm", "contextRef": "duration_2022-07-07_to_2022-07-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.tscan.com//20220707/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001193125-22-189000-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-189000-xbrl.zip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